Log In
BCIQ
Print this Print this
 

KY1003

  Manage Alerts
Collapse Summary General Information
Company Kymab Group Ltd.
DescriptionAnti-programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) mAb
Molecular Target Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today